definiens: ) ; WHEREAS, Paddock filed with the FDA ( as defined below ) ANDA ( as defined below ) [ * * * ] ( the ) requesting approval from the FDA to market a generic product containing N -acetylcysteine as its active ingredient in an amount of 6gm/30ml ( 200mg / ml ) and in an intravenous injectable dosage form [ * * * ] ; WHEREAS, Perrigo, the parent company of Paddock, filed with the FDA ANDA [ * * * ] ( the ) requesting approval from the FDA to market a generic product containing N -acetylcysteine in an amount of 6gm/30ml ( 200mg / ml ) and in an intravenous injectable dosage form as its active ingredient ; [ * * * ] WHEREAS, Cumberland filed Civil Action No . 12 -CV-00619 ( LPS ) in the United States District Court for the District of Delaware ( the ), in which Cumberland alleges that Defendants, by filing of the Paddock ANDA, infringed the ’ 356 Patent as specified therein ; WHEREAS, Cumberland filed Civil Action No . 12 -CV-06327 in the United States District Court for the Northern District of Illinois Eastern Division, in which Cumberland alleges that Perrigo, by filing of the Perrigo ANDA, infringed the ’ 356 Patent as specified therein ( the, and with the First Action, the ) ; and WHEREAS, Cumberland and Defendants have settled the Actions pursuant to the terms of the Settleme nt Agreement ( the ) between the Parties, dated as of the date hereof, and pursuant to the Settlement Agreement have agreed to enter into this Agreement, pursuant to which Cumberland will agree to supply Perrigo, [ * * * ], with an authori zed generic version of the Acetadote ® [ * * * ] Product and license Perrigo to sell such authorized generic versions, in each case on the terms and conditions contained herein